Article
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Disease markers - 1 Jan 2022
Castaño-Bonilla Tamara, Barragán Eva, Sargas Claudia, Sanz Alejandro, Algarra Lorenzo, Herrera-Puente Pilar, García-Boyero Raimundo, Barrios Manuel, Martinez-Cuadron David, Rodriguez-Veiga Rebeca, Boluda Blanca, Gil Cristina, Serrano-López Josefina, Martínez-López Joaquín, Sayas-Lloris María José, Olave María Teresa, Riaza-Grau Rosalía, Castillo Teresa Bernal-Del, Larrayoz María José, Amigo Raquel, Jiménez-Velasco Antonio, Sánchez Joaquín, Ayala Rosa, Blas Carlos, Lainez Daniel, Serrano-López Juana, Sanz Miguel A, Alonso-Domínguez Juan M, Montesinos Pau
Abstract excerpt
Gemtuzumab ozogamicin (GO) is a conjugate of a monoclonal antibody and calicheamicin, which has been reapproved for the treatment of acute myeloid leukemia (AML). AML patients with the CD33 rs12459419 CC genotype might benefit from the addition of GO to intensive treatment in contrast to patients with CT/TT genotypes. Nevertheless, contradictory results have been reported. We sought to shed light on the...
Read the complete abstract on PubMed